Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H34FN7O4.CH4O3S |
| Molecular Weight | 575.654 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC1=NC(NNC(=O)[C@H](CC2CCCC2)CN(O)C=O)=C(F)C(=N1)N3CCN4CCOC[C@@H]4C3
InChI
InChIKey=UNGNACZMQRGYNV-URBRKQAFSA-N
InChI=1S/C22H34FN7O4.CH4O3S/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16;1-5(2,3)4/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26);1H3,(H,2,3,4)/t17-,18+;/m1./s1
| Molecular Formula | C22H34FN7O4 |
| Molecular Weight | 479.5483 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | CH4O3S |
| Molecular Weight | 96.106 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. | 2013-05 |
|
| Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. | 2013-05 |
|
| Antibiotics in development targeting protein synthesis. | 2011-12 |
|
| Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. | 2011-11 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23478958
Lanopepden (GSK1322322) had an MIC90 of 1 μg/ml against M. catarrhalis and 4 μg/ml against H. influenzae, with 88.8% of beta-lactamase-positive strains showing growth inhibition at that concentration. All S. pneumoniae strains were inhibited by ≤ 4 μg/ml of GSK1322322, with an MIC90 of 2 μg/ml. GSK1322322 was very potent against S. pyogenes strains, with an MIC90 of 0.5 μg/ml, irrespective of their macrolide resistance phenotype. It was also active against S. aureus strains regardless of their susceptibility to methicillin, macrolides, or levofloxacin, with an MIC90 of 4 μg/ml in all cases.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:36:08 GMT 2025
by
admin
on
Mon Mar 31 23:36:08 GMT 2025
|
| Record UNII |
YW25HPP501
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL3301608
Created by
admin on Mon Mar 31 23:36:08 GMT 2025 , Edited by admin on Mon Mar 31 23:36:08 GMT 2025
|
PRIMARY | |||
|
300000044500
Created by
admin on Mon Mar 31 23:36:08 GMT 2025 , Edited by admin on Mon Mar 31 23:36:08 GMT 2025
|
PRIMARY | |||
|
DBSALT002104
Created by
admin on Mon Mar 31 23:36:08 GMT 2025 , Edited by admin on Mon Mar 31 23:36:08 GMT 2025
|
PRIMARY | |||
|
1441390-17-5
Created by
admin on Mon Mar 31 23:36:08 GMT 2025 , Edited by admin on Mon Mar 31 23:36:08 GMT 2025
|
PRIMARY | |||
|
71571564
Created by
admin on Mon Mar 31 23:36:08 GMT 2025 , Edited by admin on Mon Mar 31 23:36:08 GMT 2025
|
PRIMARY | |||
|
C170093
Created by
admin on Mon Mar 31 23:36:08 GMT 2025 , Edited by admin on Mon Mar 31 23:36:08 GMT 2025
|
PRIMARY | |||
|
YW25HPP501
Created by
admin on Mon Mar 31 23:36:08 GMT 2025 , Edited by admin on Mon Mar 31 23:36:08 GMT 2025
|
PRIMARY | |||
|
BC-71
Created by
admin on Mon Mar 31 23:36:08 GMT 2025 , Edited by admin on Mon Mar 31 23:36:08 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |